"Valproic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
| Descriptor ID |
D014635
|
| MeSH Number(s) |
D02.241.081.944.509.900 D10.251.400.895.593.900
|
| Concept/Terms |
Valproic Acid- Valproic Acid
- Propylisopropylacetic Acid
- 2-Propylpentanoic Acid
- 2 Propylpentanoic Acid
- Divalproex
Divalproex Sodium- Divalproex Sodium
- Semisodium Valproate
- Valproic Acid, Sodium Salt (2:1)
|
Below are MeSH descriptors whose meaning is more general than "Valproic Acid".
Below are MeSH descriptors whose meaning is more specific than "Valproic Acid".
This graph shows the total number of publications written about "Valproic Acid" by people in this website by year, and whether "Valproic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 4 | 0 | 4 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Valproic Acid" by people in Profiles.
-
Valproic Acid Serum Concentration and Incidence of Toxicity in Pediatric Patients. J Child Neurol. 2022 05; 37(6):461-470.
-
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.
-
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.
-
Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.
-
The established status epilepticus trial 2013. Epilepsia. 2013 Sep; 54 Suppl 6:89-92.
-
Treatment of status epilepticus: an international survey of experts. Neurocrit Care. 2013 Apr; 18(2):193-200.
-
Medically intractable temporal lobe epilepsy in patients with normal MRI: surgical outcome in twenty-one consecutive patients. Seizure. 2011 Jul; 20(6):475-9.
-
Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010 Mar; 35(4):990-8.
-
Integrated treatment of aggression in the context of ADHD in children refractory to stimulant monotherapy: a window into the future of child psychopharmacology. Am J Psychiatry. 2009 Dec; 166(12):1315-7.
-
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19; 22(10):1131-5.